GMDA News and Press, Gamida Cell Ltd. From 02/16/21

Gamida Cell (GMDA) sold its $75M of 5.875% exchangeable senior notes due in 2026 to certain funds managed by Highbridge Capital Management.Proceeds along with proceeds of earlier sale of $75M ordinary shares in December 2020 are expected to provide Gamida Cell with sufficient liquidity to fun...

Pro forma Cash Expected to Fund Manufacturing, Regulatory and Commercial Readiness Preparations for Omidubicel and the Advancement of GDA-201 Clinical Development Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commer...

Anchiano Therapeutics (ANCN) -28%.Pulmatrix (PULM) -21% on direct offering.United States Antimony (UAMY) -21% on direct offering.Cancer Genetics (CGIX) -21% on stock offering.BioHiTech Global (BHTG) -15%.Fluidigm (FLDM) -14% on Q4 earnings; inks distrib...

Shares of biotech company Gamida Cell (NASDAQ: GMDA) are blasting higher on Wednesday following the company's release of data from a phase 3 clinical trial for one of its leading pipeline candidates, Omidubicel. As of 2:12 p.m. EST, Gamida's stock was up by 25.9%, after jumping by a...

Gainers: Bio-Path BPTH +261%, Cancer Genetics (CGIX) +120%, Sundial Growers (SNDL) +31%, Gamida Cell (GMDA) +26%, Clever Leaves (CLVR) +22%.Losers: Neovasc NVCN -28%, Panbela Therapeutics PBLA -24%, Ocugen (OCGN) -19%, Aeterna Z...

Cancer Genetics (CGIX) +131%.The OLB Group (OLB) +83% on plan to offer Cryptocurrency payment options via blockchain technology.BioHiTech Global (BHTG) +66%.Bio-Path Holdings (BPTH) +50%.Neptune Wellness Solutions (NEPT) +48% on acquisition of organic baby food maker Sprout Foods.Ga...

Gamida Cell (GMDA) announces positive results from a Phase 3 clinical study of its advanced cell therapy omidubicel in certain patients with hematologic malignancies.Gamida said that it expects to submit a Biologics License Application for the treatment to the U.S. FDA in the s...

— Omidubicel represents a potentially transformative cell therapy treatment option for patients in need of a bone marrow transplant — —Newly presented data support clinical benefit demonstrated by primary and secondary endpoints— —Com...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transp...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in January: H.C. Wainwright Bioconnect 2021 Conference, ...